Ascendis Pharma A/S (ASND) Receives Daily Media Sentiment Score of 0.20

News headlines about Ascendis Pharma A/S (NASDAQ:ASND) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ascendis Pharma A/S earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.8300524373886 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the media headlines that may have effected Accern’s scoring:

Ascendis Pharma A/S (NASDAQ:ASND) opened at $40.10 on Wednesday. The company has a market capitalization of $1,435.37, a PE ratio of -11.02 and a beta of 0.70. Ascendis Pharma A/S has a 52 week low of $19.21 and a 52 week high of $42.00.

ASND has been the subject of a number of research reports. Leerink Swann reissued a “hold” rating and set a $28.00 target price on shares of Ascendis Pharma A/S in a report on Friday, September 1st. Wedbush reissued an “outperform” rating and set a $10.71 target price (down previously from $65.00) on shares of Ascendis Pharma A/S in a report on Friday, September 22nd. Credit Suisse Group reissued an “outperform” rating and set a $50.00 target price (up previously from $30.00) on shares of Ascendis Pharma A/S in a report on Friday, September 22nd. Wells Fargo & Co reissued a “buy” rating and set a $51.00 target price on shares of Ascendis Pharma A/S in a report on Friday, September 22nd. Finally, Bank of America reissued a “buy” rating and set a $36.00 target price (up previously from $34.00) on shares of Ascendis Pharma A/S in a report on Monday, September 25th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $36.45.

ILLEGAL ACTIVITY WARNING: “Ascendis Pharma A/S (ASND) Receives Daily Media Sentiment Score of 0.20” was first published by Week Herald and is owned by of Week Herald. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://weekherald.com/2017/12/27/ascendis-pharma-as-asnd-receives-daily-media-sentiment-score-of-0-20.html.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Insider Buying and Selling by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply